VBIO
Valion Bio Inc. Common Stock (VBIO)
Healthcare • NASDAQ • $0.96-7.69%
- Symbol
- VBIO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.96
- Daily Change
- -7.69%
- Market Cap
- $3.01M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $5.60
- 52W Low
- $0.72
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 1.87
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Company websiteResearch VBIO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.